Patents by Inventor Mandy LOO
Mandy LOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399312Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: April 27, 2023Publication date: December 14, 2023Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
-
Publication number: 20230218597Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: January 4, 2023Publication date: July 13, 2023Inventors: Christina Owens, Svitlana Kulyk, Steven D.E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Chen Zhao, Erik Fenster, Adam D. Hughes
-
Patent number: 11673879Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: GrantFiled: March 30, 2021Date of Patent: June 13, 2023Assignee: Theravance Biopharma R&D IP, LLCInventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
-
Patent number: 11608354Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: GrantFiled: February 22, 2021Date of Patent: March 21, 2023Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
-
Patent number: 11590116Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: GrantFiled: November 20, 2020Date of Patent: February 28, 2023Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Christina Owens, Svitlana Kulyk, Steven D. E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Erik Fenster, Adam D. Hughes
-
Publication number: 20220372015Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: March 30, 2021Publication date: November 24, 2022Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
-
Publication number: 20210179655Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: ApplicationFiled: February 22, 2021Publication date: June 17, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo, Patrick J. Brassil
-
Publication number: 20210154179Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: November 20, 2020Publication date: May 27, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Christina Owens, Svitlana Kulyk, Steven D.E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Erik Fenster, Adam D. Hughes
-
Patent number: 10961267Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: GrantFiled: August 29, 2019Date of Patent: March 30, 2021Assignee: Theravance Biopharma R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
-
Publication number: 20190389895Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: ApplicationFiled: August 29, 2019Publication date: December 26, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo, Patrick J. Brassil
-
Patent number: 10435428Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: GrantFiled: November 22, 2016Date of Patent: October 8, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
-
Patent number: 10392368Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 31, 2018Date of Patent: August 27, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Erik Fenster, Tom M. Lam, Mandy Loo, Robert Murray McKinnell, Anthony Francesco Palermo, Diana Jin Wang, Breena Fraga, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Publication number: 20190040043Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: July 31, 2018Publication date: February 7, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ERIK FENSTER, TOM M. LAM, MANDY LOO, ROBERT MURRAY MCKINNELL, ANTHONY FRANCESCO PALERMO, DIANA JIN WANG, BREENA FRAGA, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
-
Patent number: 9669027Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: October 15, 2015Date of Patent: June 6, 2017Assignee: Theravance Biopharma R&D IP, LLCInventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
-
Publication number: 20170145044Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: ApplicationFiled: November 22, 2016Publication date: May 25, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo
-
Patent number: 9260414Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 12, 2014Date of Patent: February 16, 2016Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Publication number: 20160038483Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: October 15, 2015Publication date: February 11, 2016Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
-
Patent number: 9212168Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 2, 2012Date of Patent: December 15, 2015Assignee: Theravance Biopharma R&D IP, LLCInventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
-
Publication number: 20150071878Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 12, 2014Publication date: March 12, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Patent number: 8921372Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 3, 2011Date of Patent: December 30, 2014Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Daniel D. Long, Lori Jean Van Orden, Lan Jiang, Mandy Loo, Daisuke Roland Saito, Sheila Zipfel, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa, Xiaojun Huang, Weijiang Zhang
